Findings from a retrospective cohort study found that immune checkpoint inhibitors induced promising responses in the first- and second-line treatment of head and neck squamous cell carcinoma.
Nicholas Wrigley
Advertisement
Articles by Nicholas Wrigley
Advertisement
Latest Updated Articles
Data Support the Use of First-/Second-Line Immune Checkpoint Inhibitors in HNSCCPublished: December 2nd 2022 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
3
Experts See Promise in AI for Atopic Dermatitis Care
4
New Analysis Finds Radiofrequency Microneedling Superior for Rosacea Erythema and Patient Satisfaction
5
